Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 28, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback transaction:
- Shares Purchased: 935,000 ordinary shares of 25 pence each.
- Purchase Price: 1,336.8745 pence per share.
- Treasury Shares Held: 226,769,678 shares following the transaction.
- Shares in Issue: 5,762,784,548 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback executed on November 28, 2006, authorized by shareholders at the Annual General Meeting on May 17, 2006. The acquired shares are intended to be held in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the 935,000 shares purchased at 1,336.8745 pence per share.
- Confirm the updated total share capital and Treasury holdings as of the filing date.
- Review the Annual General Meeting minutes from May 17, 2006, to understand the full scope of the share repurchase authority granted.